132 related articles for article (PubMed ID: 31115210)
1. Prognostic Value of PD-L1 in Patients with Hepatocellular Carcinoma.
Pei R; Zhang W; Wang S; Huang X; Zou Y
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115210
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PD-L1 and PD-L2 Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma.
Jung HI; Jeong D; Ji S; Ahn TS; Bae SH; Chin S; Chung JC; Kim HC; Lee MS; Baek MJ
Cancer Res Treat; 2017 Jan; 49(1):246-254. PubMed ID: 27456947
[TBL] [Abstract][Full Text] [Related]
3. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Kan G; Dong W
Eur Rev Med Pharmacol Sci; 2015 Aug; 19(16):3063-71. PubMed ID: 26367730
[TBL] [Abstract][Full Text] [Related]
4. Programmed cell death-ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics.
Mou H; Yang QA; Yu L; Wang T; Liu K; Shen R; Pan X; Dai Y; Wan Q; Zhou F; Qian L; Chen D; Yau T; Dong X; Wang X; Wang S
J Gastroenterol Hepatol; 2021 Sep; 36(9):2601-2609. PubMed ID: 33656759
[TBL] [Abstract][Full Text] [Related]
5. Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features.
Calderaro J; Rousseau B; Amaddeo G; Mercey M; Charpy C; Costentin C; Luciani A; Zafrani ES; Laurent A; Azoulay D; Lafdil F; Pawlotsky JM
Hepatology; 2016 Dec; 64(6):2038-2046. PubMed ID: 27359084
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathologic Significance and Prognostic Value of Programmed Cell Death Ligand 1 (PD-L1) in Patients With Hepatocellular Carcinoma: A Meta-Analysis.
Li JH; Ma WJ; Wang GG; Jiang X; Chen X; Wu L; Liu ZS; Zeng XT; Zhou FL; Yuan YF
Front Immunol; 2018; 9():2077. PubMed ID: 30254644
[No Abstract] [Full Text] [Related]
7. Prognostic value of PD-1 and PD-L1 expression in patients with metastatic clear cell renal cell carcinoma.
Ueda K; Suekane S; Kurose H; Chikui K; Nakiri M; Nishihara K; Matsuo M; Kawahara A; Yano H; Igawa T
Urol Oncol; 2018 Nov; 36(11):499.e9-499.e16. PubMed ID: 30131293
[TBL] [Abstract][Full Text] [Related]
8. PD-L1
Zhou L; Wang J; Lyu SC; Pan LC; Shi XJ; Du GS; He Q
Technol Cancer Res Treat; 2021; 20():15330338211045820. PubMed ID: 34605709
[No Abstract] [Full Text] [Related]
9. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma.
Yugawa K; Itoh S; Yoshizumi T; Iseda N; Tomiyama T; Morinaga A; Toshima T; Harada N; Kohashi K; Oda Y; Mori M
Hepatol Commun; 2021 Feb; 5(2):334-348. PubMed ID: 33553979
[TBL] [Abstract][Full Text] [Related]
10. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
11. Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma.
Liu CQ; Xu J; Zhou ZG; Jin LL; Yu XJ; Xiao G; Lin J; Zhuang SM; Zhang YJ; Zheng L
Br J Cancer; 2018 Jul; 119(1):80-88. PubMed ID: 29921949
[TBL] [Abstract][Full Text] [Related]
12. The expression of PD-L1 APE1 and P53 in hepatocellular carcinoma and its relationship to clinical pathology.
Berretta M; Stanzione B; Di Francia R; Tirelli U
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4207-9. PubMed ID: 26636502
[No Abstract] [Full Text] [Related]
13. Transarterial chemoembolisation enhances programmed death-1 and programmed death-ligand 1 expression in hepatocellular carcinoma.
Montasser A; Beaufrère A; Cauchy F; Bouattour M; Soubrane O; Albuquerque M; Paradis V
Histopathology; 2021 Jul; 79(1):36-46. PubMed ID: 33326644
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 expression in malignant salivary gland tumors.
Harada K; Ferdous T; Ueyama Y
BMC Cancer; 2018 Feb; 18(1):156. PubMed ID: 29409471
[TBL] [Abstract][Full Text] [Related]
15. High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis.
Finkelmeier F; Canli Ö; Tal A; Pleli T; Trojan J; Schmidt M; Kronenberger B; Zeuzem S; Piiper A; Greten FR; Waidmann O
Eur J Cancer; 2016 May; 59():152-159. PubMed ID: 27039170
[TBL] [Abstract][Full Text] [Related]
16. The correlation and prognostic value of serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death-ligand 1 (sPD-L1) in patients with hepatocellular carcinoma.
Chang B; Huang T; Wei H; Shen L; Zhu D; He W; Chen Q; Zhang H; Li Y; Huang R; Li W; Wu P
Cancer Immunol Immunother; 2019 Mar; 68(3):353-363. PubMed ID: 30506460
[TBL] [Abstract][Full Text] [Related]
17. Study of Serum Soluble Programmed Death Ligand 1 as a Prognostic Factor in Hepatocellular Carcinoma in Egyptian Patients.
El-Gebaly F; Abou-Saif S; Elkadeem M; Helmy A; Abd-Elsalam S; Yousef M; Elkhouly RA; Amer IF; El-Demerdash T
Curr Cancer Drug Targets; 2019; 19(11):896-905. PubMed ID: 31538897
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of PD-L1 expression and CD8+ T cell infiltration in pulmonary neuroendocrine tumors.
Wang H; Li Z; Dong B; Sun W; Yang X; Liu R; Zhou L; Huang X; Jia L; Lin D
Diagn Pathol; 2018 May; 13(1):30. PubMed ID: 29789013
[TBL] [Abstract][Full Text] [Related]
19. Upregulation of circulating PD-L1/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma.
Zeng Z; Shi F; Zhou L; Zhang MN; Chen Y; Chang XJ; Lu YY; Bai WL; Qu JH; Wang CP; Wang H; Lou M; Wang FS; Lv JY; Yang YP
PLoS One; 2011; 6(9):e23621. PubMed ID: 21912640
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
